LIXTE Biotechnology announced it has received a Notice of Allowance from the United States Patent and Trademark Office, USPTO, for U.S. Patent application number 16/467,721, titled, “Oxabicycloheptanes for Modulation of Immune Response,” for combining the Company’s LB-100 compound with various innovative cancer immunotherapies. “The patent award further bolsters LIXTE’s existing intellectual property portfolio and underscores the Company’s commitment to pioneering research and delivering innovative solutions to patients battling cancer,” said Bas van der Baan, LIXTE’s Chief Executive Officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIXT:
- LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
- First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
- Lixte Biotechnology announces first patient dosed in trial with NKI
- Lixte Biotechnology provides update on recent activities, developments
- LIXTE Biotechnology Provides Update On Recent Activities and Developments